We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00645294
First Posted: March 27, 2008
Last Update Posted: March 27, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Gilead Sciences
March 21, 2008
March 27, 2008
March 27, 2008
February 2003
August 2003   (Final data collection date for primary outcome measure)
To characterize the PK profile of adefovir 0.14 mg/kg and 0.3 mg/kg in children 2-11 years, including dose proportionality of adefovir dipivoxil liquid formulation. To characterize the PK profile of adefovir dipivoxil 10 mg in adoloscents 12-17 years. [ Time Frame: 8 days ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV
A Phase 1-2 Open-Label Study of the Pharmacokinetics and Safety of a Single Dose of Adefovir Dipivoxil in Children and Adolescents (Aged 2-17) With Chronic Hepatitis B
Open-label study of the pharmacokinetics of adefovir dipivoxil in children and adolescents infected with chronic hepatitis B.
Children and adolescents with chronic hepatitis B and compensated liver, HBeAg-positive and serum HBV DNA positive (greater than or equal to 1 x 100,000 copies/mL by Roche Amplicor Monitor PCR) received doses of adefovir dipivoxil in a cross-over design. Subjects aged 2-11 received two single doses (0.14 mg/kg and 0.3 mg/kg liquid formulation) and subjects 2-17 received one dose (10 mg liquid formulation).
Interventional
Phase 1
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Hepatitis B
  • Drug: Adefovir dipivoxil
    0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
  • Drug: Adefovir Dipivoxil
    0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
  • Drug: Adefovir Dipivoxil
    ADV 10 mg on Day 1
  • Treatment Group A
    ADV (0.14 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.3 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
    Intervention: Drug: Adefovir dipivoxil
  • Treatment Group B
    ADV (0.3 mg/kg) oral suspension formulation on Day 1 followed by ADV (0.14 mg/kg) oral suspension formulation on Day 8 in 2-6 and 7-11 year old age group
    Intervention: Drug: Adefovir Dipivoxil
  • Treatment Group C
    ADV 10 mg single dose on Day 1 in 12-17 year old age group
    Intervention: Drug: Adefovir Dipivoxil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
47
August 2003
August 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females between the ages of 2 and 17 (inclusive) with chronic hepatitis B as evidenced by the following:
  • HBsAg positive for a minimum of 6 months
  • HBeAg positive and HBV DNA greater than or equal to 1 x 100,000 copies/mL at screening
  • Children and adolescents with compensated liver disease
  • ALT levels greater than or equal to 1.2 upper limit of normal (applicable to 7- to 17-year-old children and adolescents only)
Sexes Eligible for Study: All
2 Years to 17 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Germany,   Poland,   United Kingdom
 
 
NCT00645294
GS-02-517
No
Not Provided
Not Provided
Elsa Mondou, MD, Gilead Sciences
Gilead Sciences
Not Provided
Not Provided
Gilead Sciences
March 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP